Loading...
  • AHSCT
  • Conclusions This study confirms that AHSCT in selected patients with severe dcSSc results in sustained improvement of skin thickening and stabilizations of organ function up to 10 years after transplantation, so leading to a global clinical improvement, as showed by the persistent reduction in the ESSG clinical activity score. (bmj.com)
  • high-dose therapy
  • Nevertheless, high dose therapy with reinfusion of HSCs is commonly used in the hematopoietic malignancies, and if the transduction efficiency can be improved then the therapeutic possibilities are great, limited only by the number of useful genes available. (biomedcentral.com)
  • study
  • To determine whether retrovirus-mediated transfer of MDR1 to human hematopoietic cells would result in their stable engraftment and possibly their expansion, and to study the effects on this population of cells of treatment with myelosuppressive doses of paclitaxel. (biomedcentral.com)
  • patient
  • Patient characteristics before transplantation were examined by univariate analysis using the log-rank test and by Cox's proportional hazards regression analysis to determine predictors of PFS. (bloodjournal.org)
  • If a patient's hematopoetic system was reconstituted using cells containing this gene, then there is the potential to further treat the patient with drugs such as paclitaxel without causing significant hematopoietic toxicity. (biomedcentral.com)